Affiliation:
1. Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, New Jersey
Abstract
Sulforhodmaine B lowers T in alveolar edema liquid. Given the problematic intratracheal delivery of surfactant therapy for ARDS, intravenous SRB might constitute an alternative therapeutic. In a lung injury model, we find that intravenously administered SRB crosses the injured alveolar-capillary barrier, reduces T specifically in injured lung regions, improves oxygenation, and reduces the degree of further lung injury. Intravenous SRB administration might help respiratory distress patients, including those with the novel coronavirus, avoid mechanical ventilation or, once ventilated, survive.
Funder
HHS | NIH | National Heart, Lung, and Blood Institute
Publisher
American Physiological Society
Subject
Physiology (medical),Physiology
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献